BACKGROUND: Analysis of trace proteins plays an essential role in the fields of biomedical research and clinical diagnosis. Development of methods for the detection of proteins at very low concentrations has historically been a challenge in immunochemistry. We have developed an electrical immunosensor for the detection of prostate specific antigen (PSA).
Analysis of low concentrations of proteins is important in the fields of biomedical research, food and environmental analysis, and clinical diagnosis. Development of methods for detection of proteins at very low concentrations has been a long-sought goal in immunochemistry. Enhancement of protein immunoassay performance has been achieved through cascade enzymatic transformation (1) (2) (3) , nanostructured or polymeric reporters (4 -6 ) , and nucleic acid-based biological amplification (7) (8) (9) . These strategies have been successfully implemented in various optical or electrical transducers for immunological protein detection. Among them, electrochemical immunosensors are of particular value due to their low limits of detection, low cost, simple instrumentation, and low endogenous background. A variety of techniques have been introduced for the construction of sensitive electrochemical immunosensors based on enzyme-catalyzed signal amplification or transduction mechanisms (4, 10 -15 ) , as well as nanoscale carriers or reporters including metal or semiconductor nanoparticles (16) (17) (18) (19) (20) (21) . Biological amplification based on nucleic acid labels has also been shown to provide enhanced electrochemical detection of proteins (15, 22 ) . Most of these electrochemical signal amplification strategies have remained at the laboratory-development level, with the analytical protocols comprising skill-demanding operations and specifically synthesized labels.
Electrical transducers, in which electrical resistance (conductance) or capacitance is measured in relation to a biological recognition event, have been investigated because of their compatibility with advanced semiconductor technology and large-scale reproducible fabrication and miniaturization. Electrical biosensors with surface active components are able to alleviate possible perturbations to interfacial biochemical and electrochemical processes, allowing for the development of high-performance biosensors (23) (24) (25) (26) . Pilot studies of electrical biosensors included the use of a pair of microgapped electrodes between which gold colloids were localized by biological binding events, followed by silver enhancement promoted by these nanoparticles (27, 28 ) . This technique was reported to give a detection limit as low as 500 fmol/L via a simple conductance readout (27 ) . Successful applications of this technique were demonstrated in a variety of bioassays with a further extension of biobar code technology (29 -31 ) . Very recently, a modified strategy using a nanogapped microelectrode array for electrical detection of microRNA (a class of small, non-proteincoding RNA molecules that play roles in gene expression regulation in a broad range of plants, viruses, and mammals) was developed based on in situ hybridtemplated formation of electrically conducting polyaniline nanowires (32 ) . This strategy eliminated the second hybridization with a nanoparticle-labeled probe, offering a detection limit of 5 fmol/L target (32 ) . However, both gold colloid-seeded growth of silver nanoparticles and peptide nucleic acid (PNA) 1 /RNA hybrid-templated formation of polyaniline nanowires are chemical processes that might be susceptible to nonspecific enhancement reactions. Exploitation for analyte-specific enhancement is of considerable interest in developing electrical biosensors with improved detection limits and adaptability for the detection of trace protein biomarkers.
We report the development of a novel ultrasensitive electrical immunosensor using a microgapped interdigitated electrode array (MGIDEA) based on an enzyme-linked immunoassay format with enzymatic silver deposition for the detection of a tumor biomarker of prostate specific antigen (PSA).
Materials and Methods

MATERIALS AND REAGENTS
PSA140 monoclonal antibody (mAb) and PSA103 mAb were obtained from Tianjiang Biotechnology Ltd. Alkaline phosphatase (ALP), (3-aminopropyl)triethoxysilane (APTES), 4-methylumbelliferyl phosphate, and ascorbic acid 2-phosphatase (AAP) were the products of Sigma. Glutaraldehyde, BSA, human serum albumin (HSA), human immunoglobulin G (hIgG), hIgE, and sera of goat, cow, rabbit, mouse, sheep, guinea pig, chicken, and pig were obtained from Dingguo Biological Product Company. PSA, carcinoembryonic antigen (CEA), and ␣-fetoprotein (AFP) were purchased from National Institute for Control of Pharmaceutical and Biological Products. PSA chemiluminescent immunoassay kit was purchased from Autobio Co. Ltd. Other reagents and chemicals were all of analytical reagent grade. All solutions were prepared with ultrapure water of 18 mol/L⍀ purified from a MilliQ purification system. We used 2 buffers: 10 mmol/L PBS (0.1 mol/L NaCl, pH 7.4) and 20 mmol/L Tris-HCl buffer (pH 8.0).
We collected blood specimens from patients with prostate diseases in the Third Xiangya Hospital via venipuncture in tubes containing 0.13 mol/L sodium citrate (1 part citrate and 9 parts blood by volume). Specimens were stored at room temperature for 2-3 h. Each specimen was centrifuged at 2000g/min for 30 min, and the plasma was stored at Ϫ20°C and thawed immediately before analysis. Each aliquot was thawed only once. The plasma was diluted 1000-fold before assay with 10 mmol/L PBS or sera from different animals.
PREPARATION OF mAb-ALP CONJUGATE
The preparation of PSA103 mAb-ALP conjugate was performed according to a 1-step method documented previously (33 ) . Briefly, we added 20 L 2.5% glutaraldehyde to 1 mL PBS solution containing 2 g/L PSA103 mAb and 5 g/L ALP and allowed the reaction to occur for 2 h at room temperature. The reaction mixture was then dialyzed overnight at 4°C in PBS and Tris-HCl buffer, respectively. After dilution to 4 mL with Tris-HCl buffer containing 1% BSA followed by the addition of 1.6 mL glycerin, the resulting solution of PSA103 Mab-ALP conjugate was stored at Ϫ20°C before use.
FABRICATION OF mAb-MODIFIED MGIDEA
We fabricated the MGIDEA using standard photolithography on a ceramic wafer substrate (99.7% Al 2 O 3 ) (34 ) . The MGIDEA comprised a pair of interdigitated comb-like microelectrodes (100-nm-thick gold and 10-nm-thick titanium bilayer) with 18 fingers, as depicted in Supplemental Fig. 1 , which accompanies the online version of this article at http://www.clinchem. org/content/vol56/issue5. The fingers were each 80 m wide and 3 mm long with an 80-m gap. To immobilize biomolecules on the gaps, we sanitized the MGIDEA substrate as follows. The MGIDEA was rinsed thoroughly with absolute ethanol and acetone to remove possible organic contaminants. The MGIDEA was then immersed in piranha solution (7:3 mixture of concentrated H 2 SO 4 and H 2 O 2 ) for 10 min, followed by a rinse with 1.0 mol/L NaOH and a thorough wash with H 2 O, and air-dried. The cleaned MGIDEA was immersed in absolute ethanol containing 2.5% APTES and 1% H 2 O for 24 h. After being rinsed thoroughly with absolute ethanol, the MGIDEA was dried under nitrogen flow and stored at 4°C for 1 h.
We performed the immobilization of PSA140 mAb on the MGIDEA as follows. The silanized MGIDEA was immersed in 5.0% glutaraldehyde solu-tion for 1 h, followed by a rinse with water. Next, the MGIDEA was incubated in PBS containing 0.1 g/L PSA140 mAb for 1 h at 37°C. The MGIDEA was then washed twice with 5 mL PBS to remove excess and weakly bound protein, followed by incubation in 1% BSA for 1 h at 37°C to block nonspecific adsorption sites on the MGIDEA. The mAb-modified MGIDEA was rinsed with water followed by immediate use or storage at 4°C for future use.
ANALYTICAL PROTOCOL OF MGIDEA-BASED IMMUNOSENSOR
On the PSA140 mAb-modified MGIDEA, 20 L sample solution containing varying concentrations of PSA and 4 L PSA103 mAb-ALP conjugate was added and incubated at 37°C for 30 min. After washing the MGIDEA thoroughly with PBS, 25 L silver deposition solution (0.1 mol/L glycin-NaOH containing 1 mmol/L AAP and 5 mmol/L AgNO 3 , pH 9.0) was added and incubated at 37°C for 10 min in the dark, allowing the reduction of silver ions to a metal deposit on the MGIDEA. The MGIDEA was then washed with water and air-dried for 5 min using a hair drier. We observed that there was no need to precisely control the incubation and drying time, and prolonged incubation and air-drying time up to 20 min had little effect on the responses.
We performed electrical measurements at room temperature using a CHI electrochemical system (760C; Shanghai Chenhua Instruments). The MGIDEA sensor was placed in air, one pole connected to the working electrode and the other pole connected to the reference and counter electrodes. The linear sweep voltammetry (LSV) was adopted within a potential range from 0 to 50 mV with a scan rate of 1 mV/s and an interval of 1 mV. The curve of current vs potential was recorded, and the electrical conductance of the MGIDEA was calculated as the analytical signal for quantitative purposes.
Fluorescence immunoassay was performed for comparison with the immunosensor. After the immunoreactions on the PSA140 mAb-modified MGIDEA with 20 L sample solution and 4 L PSA103 mAb-ALP conjugate at 37°C for 30 min, the MGIDEA support was thoroughly washed with PBS and immersed in 200 L 4-methylumbelliferyl phosphate (MUP) substrate solution (20 mmol/L Tris-HCL buffer containing 100 mol/L MUP, pH 8.0) in a cuvette and incubated at 37°C for 10 min. We added 800 L sodium carbonate solution of 0.2 mol/L to the cuvette to quench the reaction followed by immediate fluorescence measurement on a fluorescence spectrophotometer (Hitachi F-7000) at 360 nm excitation and 460 nm emission with slits of 10 nm.
Results and Discussion
ANALYTICAL PRINCIPLE OF MGIDEA-BASED ELECTRICAL IMMUNOSENSOR
The MGIDEA immunosensor was based on an enzyme-linked sandwiched immunoassay format with enzymatic silver deposition for electrical detection of PSA. The analytical principle is illustrated in Fig. 1A . PSA140 mAb is covalently immobilized on the microgaps of MGIDEA through a silanization layer for capturing the analyte protein. The introduction of a PSA sample together with PSA103 mAb-ALP conjugate re- sults in the formation of a sandwiched complex of PSA with the capture mAb and the detection mAb conjugated with ALP on the microgap surface due to the specific immunoreaction. Then, ALP on the microgap surface catalyzes the hydrolysis of AAP and produces a reductive agent, ascorbic acid, which reduces Ag ϩ ions in the deposition solution to metallic silver over the microgaps. The Ag ϩ deposition allows the microgapped interdigitated electrodes to be electrically connected, affording an increase in electrical conductance of MGIDEA that can be used for quantifying the analyte concentration. According to Ohm's law, the current through 2 poles of MGIDEA is proportional to the voltage applied on MGIDEA, with a slope equal to the electrical conductance. Thus, the electrical conductance of MGIDEA can be calculated immediately from the I-V curve obtained in LSV measurements. Fig. 1B depicts the LSV curves of the immunosensor over a potential range from 0 to 50 mV in the detection of 10 ng/L PSA and in control experiments, where PSA sample was replaced by 1 g/L BSA, and the PSA103 mAb-ALP conjugate was replaced by PSA103 mAb. The LSV curves exhibit linearity in the potential range, indicating that the MGIDEA behaves as an ideal physical resistor under the measurement conditions. The LSV curves obtained in control experiments were observed to have little deviation from those for the blank immunosensor and the unmodified MGIDEA. Electrical conductance of the immunosensor showed no marked increase after the control experiments, implying that the immunosensor demonstrated fairly low background and excellent resistance to nonspecific adsorption. In contrast, the LSV curve of the immunosensor in response to 10 ng/L PSA gave a large slope with an electrical conductance about 3241 pS, which was much greater than the approximate 81 pS for the control experiments. The MGIDEA-based immunosensor had a low limit of detection with good signalto-background ratio.
Figs. 2A and B show the micrographs obtained using JSM-6500F (JEOL) scanning electron microscopy for the MGIDEA-based immunosensor in response to 1 g/L BSA and 10 ng/L PSA, respectively. In Fig. 2A , the gold fingers are shown as clean, 80-m-wide strips with 80-m flat gaps. In contrast, in Fig. 2B , there are many microparticles densely dispersed on the gold fingers and the ceramic substrate. A further investigation of the deposited particle layer was performed using energy dispersive spectroscopy (EDS). As shown in Figs. 2C and D, in the absence of PSA, the EDS spectrum merely shows the energy peaks of Au, O, and Al, the major constituents of the MGIDEA. In the presence of PSA, a strong energy peak attributed to silver appears in the EDS spectrum. We found that with the PSA103 mAb-ALP conjugate replaced by PSA103 mAb in the analytical protocol, the scanning electron micrograph and EDS of the MGIDEA were consistent with those obtained with the immunosensor in response to 1 g/L BSA. These observations demonstrate that ALP-based enzymatic reaction offers a specific route to produce a large number of dispersed silver nanoparticles over the gap. Due to possible particle merging and tunneling of current through these dispersed nanoparticles, the metal deposits enable electrical connection of neigh- boring gold fingers and induce electrode shortcircuiting, thereby substantially increasing the electrical conductance of the MGIDEA.
Scanning electron characterization was performed for the MGIDEA detecting 100 ng/L PSA using PSA103 mAb-gold colloid followed by silver enhancement to clarify the difference between the ALP-mediated silver deposition and the gold colloid-seeded growth of silver nanoparticles (online Supplemental Fig. 2 ). Supplemental Fig. 2A and B shows that there are obvious silver stains around the gold fingers even in the absence of PSA target, indicating that gold colloid-seeded growth might be susceptible to nonspecific enhancement due to autocatalysis of gold substrate. Furthermore, we found that the presence of PSA yielded very few nanoparticles, about several hundred nanometers in diameter, localized in the microgaps. Because localized rather than dispersed silver nanoparticles over the microgaps might result in decreased efficiency in particle merging and electron tunneling through the nanoparticles, we expected that gold colloid-seeded silver enhancement would exhibit a limited increase in electrical conductance in cases of low target concentration. From the LSV curves for the MGIDEA immunosensor using silver enhancement (online Supplemental  Fig. 3) , the conductance responses for the blank and the PSA sample were calculated to be 188 and 350 pS, respectively, suggesting a relatively low signal-tobackground ratio and inferior detection capability. Based on these results, it might be expected that enzymatic silver deposition provided superior performance in such MGIDEA-based affinity biosensors due to dispersion of the silver nanoparticle products and low nonspecific deposition arising from the substrate gold electrode. Fig. 3A displays the LSV curves for the MGIDEA-based immunosensor in response to PSA samples of varying concentrations. Linear voltammetric curves were obtained for the samples indicating ideal behavior for the MGIDEA-based immunosensor as an electrical resistor. The slope of the voltammetric curves, i.e., the conductance of the immunosensor, was greater with increasing concentration of PSA. The dependence of the conductance of the immunosensor on the PSA concentration is depicted in Fig. 3B . The electrical conductance of the immunosensor exhibited a dynamic increase with increasing PSA concentration in the range from 1.0 pg/L to 10 g/L. A high dose-response sensitivity was obtained over a 6-decade linear range from 1.0 pg/L to 1.0 g/L. A detection limit of 0.9 pg/L was calculated as the PSA concentration giving the electrical conductivity response of the blank plus 3 SD. The relative SDs were 2.4%, 3.9%, 2.2%, 3.2%, 2.3%, To evaluate the selectivity of the technique, the MGIDEA-based immunosensor was investigated for the detection of possible coexisting or matrix proteins. Fig. 4 depicts the conductance signals of the immunosensor in response to different proteins. Fig. 4 shows that, for a fixed 10 ng/L concentration of PSA in PBS and bovine serum, the conductance responses exhibit only small variations, suggesting that complicated matrix such as bovine serum has little interference with the determination of PSA using this strategy. Also, in the absence of PSA, the presence of a high concentration (2 mg/L) of other proteins or matrices such as BSA, HSA, hIgG, hIgE, CEA, and AFP does not show significant conductance responses. These observations support a highly specific interaction between PSA and its monoclonal antibodies and that enzymatic silver deposition was a highly specific reaction mediated by ALP.
ASSAY PERFORMANCE
To demonstrate potential of the proposed MGIDEA-based electrical immunosensor in clinical applications, 43 human serum samples from patients with prostate diseases were measured using the MGIDEA method and compared to a chemiluminescent immunoassay. Table 1 shows that the estimated concentrations of PSA in these samples, either diluted in PBS or in sera from different animals (these animal sera did not have human PSA and served as different matrices), using the MGIDEA-based immunosensor show a deviation ranging from Ϫ7.96% to 11.13% from those obtained using chemiluminescence. These results suggest that the MGIDEA-based immunosensor was comparable to a clinical assay, and might hold promise as a viable technique for the determination of PSA in serum samples. 
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